Panomics, Inc.

Panomics, Inc. specializes in advanced molecular biology tools, focusing on gene expression analysis and protein quantification through innovative multiplex biomarker assays, supporting research in drug discovery and clinical diagnostics. Panomics, Inc. is a biotechnology company based in Fremont, US, that focuses on molecular biology and gene expression analysis.

Founded by Radu Tanasa, who has a background in biotechnology innovation, the company has undergone significant changes in its operational strategy over time. In November 2008, Panomics was acquired by Affymetrix for USD 73 mn, marking a pivotal moment in its history as it shifted to become part of a larger organization. During its operations, Panomics has completed a total of 5 deals, with its most recent deal occurring on November 12, 2008, which contributed to its total amount raised of USD 73 mn. Panomics specializes in advanced molecular biology tools and technologies, focusing primarily on gene expression analysis and protein quantification.

Their core offerings include proprietary multiplex biomarker assays that allow researchers to analyze multiple targets simultaneously in a single sample. These products are designed to enhance the efficiency and accuracy of research in fields such as drug discovery, disease biomarker identification, and clinical diagnostics. The company serves a diverse client base, which includes academic research institutions, pharmaceutical companies, and biotechnology firms, primarily in North America and Europe. By providing innovative solutions for complex biological problems, Panomics aims to facilitate breakthroughs in personalized medicine and enhance the understanding of various diseases.

Panomics generates revenue through a combination of direct sales of its assay kits and consumables alongside potential collaborative agreements with research institutions and pharmaceutical firms. The business model typically involves B2B transactions, where clients purchase products as part of their research initiatives. Transactions are structured around subscription services for recurring access to new assay developments and updates, as well as one-time purchases of their flagship products. Pricing plans for these products are tiered based on volume and specific configurations, catering to the varying needs of different research entities.

This transactional framework allows Panomics to maintain a steady revenue stream while fostering long-term partnerships within the scientific community. In the future, Panomics plans to continue expanding its product offerings with new assays designed to enhance research in personalized medicine, although specific release dates have not been detailed. The company is also focusing on expanding its market reach into additional geographical regions, particularly in Europe, aiming for a broader footprint by 2025. The recent acquisition by Affymetrix will enable Panomics to leverage additional resources for product development and market expansion, utilizing the USD 73 mn funding to support these growth initiatives.